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Overexpression of Brf1, a transcription factor of the RNA polymerase III apparatus, can transform 
cells in vitro and cause tumor formation in vivo. Marshall et al. (2008) now show that one of the 
transcriptional products of RNA polymerase III, the initiator tRNAMet, mediates this effect, revealing 
an unexpected role for this tRNA in tumorigenesis.RNA polymerase III (pol III) is the larg-
est RNA polymerase with 17 sub-
units. The products of pol III-driven 
transcription include the untranslated 
transcripts tRNA and 5S rRNA that 
are essential for translation. It is well 
established that pol III transcription 
factors are frequently overexpressed 
in a variety of cancers (White, 2004), 
but it has been unclear whether pol III 
is a causative factor in cancer because 
recurrent mutations in its subunits or 
associated transcription factors have 
not been found in tumors.
Reporting in this issue, Marshall et 
al. (2008) now reveal that overexpres-
sion of the pol III-specific transcription 
factor Brf1 in a variety of cultured cell 
lines results in their transformation as 
shown by formation of foci, growth 
in soft agar, and formation of tumors 
when injected into mice. To confirm 
that Brf1 acts through pol III transcrip-
tion, the authors performed an epista-
sis experiment in which they reduced 
the level of another component of the 
pol III apparatus, RPC39, that interacts 
with Brf1 to recruit the polymerase to 
its genetic templates. They partially 
depleted RPC39 (which is normally 
present in excess) using small-inter-
fering RNA and saw no effect on tRNA 
levels or on proliferation of cells with 
normal levels of Brf1, but they did see 
abrogation of proliferation induced by 
overexpression of Brf1. Furthermore, 
partial depletion of Brf1 in transformed 
HCT116 colon carcinoma cells lack-
ing the tumor suppressor p53 inhib-
ited foci formation and impaired cell 
proliferation. Marshall and colleagues 
then asked whether a component of 
the translation initiation complex and 
one of the transcriptional products of pol III, the initiator tRNAMet (tRNAi
Met), 
could cause transformation when over-
expressed. They show convincingly 
that transfection of cells with a plasmid 
encoding tRNAi
Met caused transforma-
tion, whereas overexpression of tRNAMet 
encoding internal methionines failed to 
do so. Therefore, increased levels of 
the translation initiator tRNAi
Met can tip 
the balance leading to transformation.
Translational control of protein syn-
thesis has recently been recognized as 
an important route to oncogenic trans-
formation. This emanates primarily from 
the unraveling of signaling pathways 
converging on translational control (Bil-
anges and Stokoe, 2007) and from the 
discovery that microRNAs, implicated 
in tumorigenesis, serve as key modula-
tors of mRNA stability and translation 
(Zhang and Coukos, 2006). Evidently, 
translational control of mRNAs plays 
a more prominent role in regulating 
which proteins are to be synthesized 
than previously assumed. From a con-
ceptual viewpoint, regulation of pro-
tein synthesis at the level of transla-
tion makes sense as it permits the cell 
to respond swiftly to quickly changing 
conditions. An elaborate control system 
has been laid down during evolution to 
achieve this. During embryogenesis, 
translational control of protein synthe-
sis enables the production of the vast 
amounts of proteins needed for accel-
erated growth. This is accompanied by 
Figure 1. Translation Initiation as a Control Node in Tumorigenesis
Translation initiation factors such as eIF2 and eIF4, the structure of mRNAs, and the translation initiator 
tRNAi
Met are important determinants of the translational control of protein synthesis. Alterations in their 
expression or activation state can promote tumorigenesis by the selective translation of mRNAs that 
confer on tumor cells the ability to become transformed and to proliferate. Components labeled in red are 
known to have oncogenic potential; the pol III-specific transcription factor Brf1 and the pol III transcrip-
tional product tRNAi
Met now can be added to this list (Marshall et al., 2008).Cell 133, April 4, 2008 ©2008 Elsevier Inc. 29
energy metabolism based on aerobic 
glycolysis rather than oxidative phos-
phorylation, which allows utilization 
of a larger fraction of the energy carri-
ers as building blocks for macromole-
cules. Most tumor cells also exploit this 
strategy to promote their own growth 
(Christofk et al., 2008).
The phosphoinositide-3 kinase (PI3K) 
signaling pathway is best known for its 
capacity to regulate cell growth and 
proliferation in response to growth fac-
tors and changes in nutrient availability 
(Manning and Cantley, 2007), thereby 
playing a pivotal role in the regulation of 
protein synthesis. Components of the 
pathway are very frequently mutated in 
cancer. A critical arm of this pathway 
regulates cap-dependent translation 
through release of the initiation fac-
tor eIF4E from 4E-BP, which seques-
ters eIF4E. This permits eIF4E to bind 
together with other eIF4 subunits to 
the methyl 7-guanosine triphosphate 
(m7GTP) cap at the 5′ end of the mRNA 
(Richter and Sonenberg, 2005). This 
complex has increased affinity for 
the preinitiation complex formed by 
tRNAi
Met and eIF2, other initiation fac-
tors, and the 40S ribosomal subunit 
(Figure 1). Both the binding of eIF4E to 
the cap and the formation of a complex 
between tRNAi
Met, eIF2, and GTP are 
critical for the initiation of translation 
and are subject to extensive control. 
The initiation factor eIF4E can act as 
an oncogene when overexpressed or 
phosphorylated on serine 209 (Wen-
del et al., 2007). Also, the overexpres-
sion of the translation elongation factor 
eEF1A, which is involved in the recruit-
ment of amino-acylated tRNAs to the 
ribosome, can cause transformation 
(Tomlinson et al., 2005), indicating that 
both translation initiation and elonga-
tion are important regulatory nodes 
with multiple inputs that can alter the 
efficiency of mRNA translation. The 
effects are both quantitative and quali-
tative: overall protein synthesis may be 
augmented, and the regulatory circuit 
may permit a shift toward the preferen-30 Cell 133, April 4, 2008 ©2008 Elsevier Inctial assembly and translation of mRNA 
subsets with particular structural fea-
tures. As a result mRNAs encoding 
cell-cycle proteins and antiapoptotic 
proteins (such as Myc, cyclin D1, and 
Mcl1) can be preferentially translated, 
providing an explanation for why over-
expression or phosphorylation of dis-
tinct initiation factors or overexpression 
of tRNAi
Met can promote transformation 
(Figure 1).
A tumor cell can escape from growth 
control through a range of genetic and 
epigenetic alterations. Almost invari-
ably, mutations are found in the path-
ways that respond to or influence nutri-
ent supply thereby providing energy as 
well as the building blocks needed for 
protein, lipid, and nucleic acid synthe-
sis. But this is also the Achilles heel of 
tumors and is exploited clinically through 
targeting of the tumor’s vasculature 
(Ferrara and Kerbel, 2005). Recently, 
new strategies have been proposed to 
specifically attack the energy metabo-
lism of tumor cells by inhibiting the M2 
variant of pyruvate kinase. This variant 
is selectively expressed by many tumor 
cells and blocking it forces tumors to 
shift from aerobic glycolysis to oxidative 
phosphorylation, thereby limiting tumor 
growth (Christofk et al., 2008).
As Marshall et al. (2008) elegantly 
show in their new study, impairing cap-
dependent translation initiation might 
be another approach for killing tumors 
by abrogating synthesis of proteins that 
are critical for their growth and prolif-
eration. In this context, partial inhibi-
tion of pol III-dependent transcription 
is of particular interest. Inhibiting an 
oncogene by targeting different path-
ways that converge on its expression 
or activity has the attraction that the 
toxic effects are limited while an effec-
tive reduction in oncogene function 
can still be achieved. Inhibition of the 
PI3K signaling pathway is one way to 
impair the synthesis of specific sub-
sets of proteins. So far, inhibition of 
this pathway has focused on blocking 
the activity of several key components .such as PI3K, Akt, and the mTOR sig-
naling complex. Inhibition of these and 
other components in the pathway can 
be relatively toxic or turn out to be inef-
fective as complex feedback loops can 
lead to compensatory activation of 
other components. Inhibiting a critical 
arm of the PI3K signaling pathway far 
downstream is therefore very attrac-
tive, especially if this can be achieved 
through several independent routes. 
The Marshall et al. study presents a new 
option for such an approach by limiting 
formation of the translation preinitia-
tion complex by blocking synthesis of 
tRNAi
Met. It will be particularly intrigu-
ing to explore combinations of inhibi-
tors that target tRNAi
Met by impairing 
pol III transcription, eIF4E-dependent 
translation initiation, and pyruvate M2 
kinase. Using combinations of inhibi-
tors targeting different processes and 
pathways may provide a synergy that 
will boost the therapeutic index of the 
drug combination. Time will tell whether 
this optimism is justified.
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